Business Description
Elicera Therapeutics AB
ISIN : SE0015382080
Share Class Description:
OSTO:ELIC: Ordinary SharesTotal Employee Number:
3Compare
Compare
Traded in other countries / regions
ELIC.Sweden8E8.Germany IPO Date
2021-06-11Description
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.88 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 26.9 | |||||
3-Year EPS without NRI Growth Rate | 27.1 | |||||
3-Year FCF Growth Rate | -2.8 | |||||
3-Year Book Growth Rate | -33.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.63 | |||||
9-Day RSI | 40.03 | |||||
14-Day RSI | 42.42 | |||||
3-1 Month Momentum % | -52.08 | |||||
6-1 Month Momentum % | -58.09 | |||||
12-1 Month Momentum % | -53.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.04 | |||||
Quick Ratio | 8.04 | |||||
Cash Ratio | 6.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.62 | |||||
ROA % | -41.8 | |||||
ROIC % | -288.17 | |||||
3-Year ROIIC % | -12.03 | |||||
ROCE % | -54.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 3.16 | |||||
PB Ratio | 7.14 | |||||
Price-to-Tangible-Book | 7.08 | |||||
EV-to-EBIT | -10.28 | |||||
EV-to-EBITDA | -10.28 | |||||
EV-to-Forward-Revenue | 61.27 | |||||
EV-to-FCF | -5.75 | |||||
| Price-to-Net-Current-Asset-Value | 7.08 | |||||
| Price-to-Net-Cash | 8.45 | |||||
Earnings Yield (Greenblatt) % | -9.73 | |||||
FCF Yield % | -15.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elicera Therapeutics AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.281 | ||
| Beta | -0.4046 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 47.59 | ||
| 14-Day RSI | 42.42 | ||
| 14-Day ATR (kr) | 0.189203 | ||
| 20-Day SMA (kr) | 2.72 | ||
| 12-1 Month Momentum % | -53.03 | ||
| 52-Week Range (kr) | 2.255 - 8.213846 | ||
| Shares Outstanding (Mil) | 66.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elicera Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elicera Therapeutics AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-27 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 36 days | ||
| General meeting for 2026 | 2026-06-25 13:00 | 2.63 (-1.87%) | ||
| Annual report for 2025 | 2026-05-25 | 3.01 (+0.17%) | ||
| First quarter earnings results for 2026 | 2026-04-21 | 4.93 (-4.89%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-13 | 4.78 (-2.19%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 5.55 (+7.34%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 6.82 (+8.53%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 4.56 (-6.49%) | ||
| General meeting for 2025 | 2025-05-15 | 4.56 (-6.49%) |
Show
Entries
Elicera Therapeutics AB Frequently Asked Questions
What is Elicera Therapeutics AB(OSTO:ELIC)'s stock price today?
The current price of OSTO:ELIC is kr2.62. The 52 week high of OSTO:ELIC is kr8.21 and 52 week low is kr2.26.
When is next earnings date of Elicera Therapeutics AB(OSTO:ELIC)?
The next earnings date of Elicera Therapeutics AB(OSTO:ELIC) is 2026-08-21.
Does Elicera Therapeutics AB(OSTO:ELIC) pay dividends? If so, how much?
Elicera Therapeutics AB(OSTO:ELIC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Elicera Therapeutics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers